AC Immune remains a high-risk, clinical-stage biotechnology firm whose financial viability is tethered to the unpredictable timing of non-recurring milestone payments rather than sustainable commercial revenue. While the company maintains a pipeline focused on...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.03+128.7% vs -$0.10 | $15M+58.2% vs $10M |
Q2 2026 Apr 30, 2026 | -$0.19+5.0% vs -$0.20 | $1M+325.0% vs $329,435 |
Q2 2026 Apr 29, 2026 | -$0.19+5.0% vs -$0.20 | $1M+325.0% vs $329,435 |
Q2 2026 Mar 13, 2026 | -$0.18+5.3% vs -$0.19 | $428,876-70.3% vs $1M |
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer's disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda Cash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027 Lausanne, Switzerland, August 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today provided a corporate and financial update for the half-year ended June 30, 2026. Martin Zügel, MD, interim CEO of AC Immune and Chair of the Board of Directors, commented: “AC Immune is moving towards key clinical milestones in two of our wholly-owned programs, a growing focus for AC Immune.
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK. Across these AAIC presentations, we are showing how AC Immune's Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets.
Benchmark ACIU against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AC Immune S.A. (ACIU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.83 | $288.02M | -3.34 | -86.92% | -1971.65% | -89.62% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $0.94 | $45.26M | -1.80 | — | — | -95.77% | — | |
| $1.27 | $54.03M | -0.91 | — | — | -685.96% | — | |
| $3.16 | $54.62M | -2.36 | — | -691.81% | — | — | |
| $227.53 | $33.62B | 25.77 | 1.39% | 8.39% | 4.52% | — |
AC Immune S.A. (ACIU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ACIU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AC Immune S.A. (ACIU) stock FAQ — growth, dividends, profitability & financials explained
AC Immune S.A. (ACIU) reported $17.5M in revenue for fiscal year 2025. This represents a 103% increase from $8.6M in 2013.
AC Immune S.A. (ACIU) saw revenue decline by 86.9% over the past year.
AC Immune S.A. (ACIU) reported a net loss of $43.2M for fiscal year 2025.
AC Immune S.A. (ACIU) has a return on equity (ROE) of -89.6%. Negative ROE indicates the company is unprofitable.
AC Immune S.A. (ACIU) had negative free cash flow of $35.0M in fiscal year 2025, likely due to heavy capital investments.
